WO2002016341A1 - Method for the preparation of citalopram - Google Patents
Method for the preparation of citalopram Download PDFInfo
- Publication number
- WO2002016341A1 WO2002016341A1 PCT/DK2001/000541 DK0100541W WO0216341A1 WO 2002016341 A1 WO2002016341 A1 WO 2002016341A1 DK 0100541 W DK0100541 W DK 0100541W WO 0216341 A1 WO0216341 A1 WO 0216341A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- aryl
- formula
- alkylamino
- Prior art date
Links
- 0 CN(C)CCCC1(c(cc2)ccc2F)OCc2cc(*)ccc12 Chemical compound CN(C)CCCC1(c(cc2)ccc2F)OCc2cc(*)ccc12 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Definitions
- the present invention relates to a method for the preparation of the well-known anti- depressant drug citalopram, l-[3-(dimethylamino)propyl]-l-(4-fluorophenyl)-l,3-dihydro-5- isobenzofurancarbonitrile, methods for the preparation of intermediates used in the preparation of citalopram, and methods for conversion of said intermediates into citalopram.
- Citalopram is a well-known antidepressant drug that has now been on the market for some years and has the following structure:
- Citalopram was first disclosed in DE 2,657,013, corresponding to US 4,136,193. This patent publication describes the preparation of citalopram by one method and outlines a further method, which may be used for preparing citalopram.
- the corresponding l-(4-fluorophenyl)-l,3-dihydro-5- isobenzofurancarbonitrile is reacted with 3-(N,N-dimethylamino)propyl-chloride in the presence of methylsulfinylmethide as condensing agent.
- the starting material was prepared from the corresponding 5-bromo derivative by reaction with cuprous cyanide.
- citalopram may be obtained by ring closure of the compound: in the presence of a dehydrating agent and subsequent exchange of the 5-bromo group with cuprous cyanide.
- the starting material of Formula II is obtained from 5-bromophthalide by two successive Grignard reactions, i.e. with 4-fluorophenyl magnesium chloride and NN- dimethylaminopropyl magnesium chloride, respectively.
- the intermediate of Formula III was prepared from 5-cyanophthalide by two successive Grignard reactions, i.e. with 4-fluorophenyl magnesium halogenide and NN- dimethylaminopropyl magnesium halogenide, respectively.
- WO 98019511 relate to methods wherein a 5-amino-, 5-alkoxycarbonyl- or 5-(sec. aminocarbonyl)phthalide is subjected to two successive Grignard reactions, ring closure and conversion of the resulting 1,3- dihydroisobenzofuran derivative to the corresponding 5-cyano compound, i.e. citalopram.
- WO 98019511 discloses a process for the manufacture of citalopram wherein a (4-substituted-2-hydroxymethylphenyl-(4-fluorophenyl)methanol compound is subjected to ring closure and the resulting 5-substituted l-(4-fluorophenyl)-l,3- dihydroisobeiizofuran converted to the corresponding 5-cyano derivative, which is alkylated with a (3-dimethylamino)propylhalogenide in order to obtain citalopram.
- methods of preparing the individual enantiomers of citalopram are disclosed in US Patent No 4,943,590 from which it also appears that the ring closure of the intermediate of Formula III may be carried out via a labile ester with a base.
- citalopram may be manufactured by a novel favourable and safe procedure using convenient starting materials.
- the present invention relates to a novel method for the preparation of citalopram having the Formula I
- the invention relates to such a method comprising:
- R is: a) An optionally substituted NH 2 , or C 1-6 alkyloxy, b) aryloxy or heteroaryloxy optionally substituted with halogen, C 1-4 -alkyl, cyano, hydroxy, C 1-4 -alkoxy, trifluoromethyl, nitro, amino, C 1-4 -alkylamino or di-C 1- - alkylamino, or c) aryl or heteroaryl optionally substituted with halogen, C 1-4 -alkyl, cyano, hydroxy, C ⁇ . 4 -alkoxy, trifluoromethyl, nitro, amino, C 1-4 -alkylamino or di-C 1-4 -alkylamino ;
- R 1 and R 2 are independently hydrogen, C 1-6 alkyl, C 1-6 alkyl substituted with one or more substituents selected from the group comprising aryl and heteroaryl, hydroxy, C 1-6 - alkoxy, aryloxy, heteroaryloxy, aryl-C 1-6 -alkoxy, or trisubstituted silyl wherein the substituents are independently C 1-6 alkyl, aryl, heteroaryl or aryl-C 1-6 -alkyl and then reacting the amide of Formula V with a dehydrating agent thereby obtaining citalopram as the base or a pharmaceutically acceptable salt thereof.
- the conversion of the 5-carboxy derivative of Formula IV to the amide of Formula V may be carried out via activated acid derivative of Formula VI:
- R 3 is halogen, C 1-6 alkoxy,aryloxy, heteroaryloxy, aryl-C ⁇ -6 -alkoxy, heteroaryl-C 1-6 - alkoxy, alkylcarbonate, arylcarbonate, alkylcarbamate, arylcarbamate, alkylthiocarbonate, arylthiocarbonate, alkylthiocarbamate, arylthiocarbamate, alkylacyloxy, arylacyloxy, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.
- the invention relates to methods for the preparation of the intermediate of Formula IV comprising conversion of a compound of Formula VIII, wherein Z is halogen to compound of Formula IV .
- the invention relates to methods for the preparation of the intermediate of Formula VII
- X is selected from halide, CN, OR 5 or SR 6 where R 5 and R° are independently selected from C 1-6 alkyl, aryl, heteroaryl or benzyl and each of these C 1-6 alkyl, aryl, heteroaryl or benzyl groups are unsubstituted or substituted with halogen, C 1-4 alkyl, cyano, hydroxy, C 1-4 alkoxy, trifluoromethyl, nitro, amino, C 1- alkylamino or di-C 1-4 alkylamino, NR 7 R 8 where R 7 and R 8 are independently selected from hydrogen, C 1-6 alkyl, aryl, heteroaryl or benzyl and each of these C 1-6 alkyl, aryl, heteroaryl or benzyl groups are unsubstituted or substituted with halogen, C 1-4 alkyl, cyano, hydroxy, C 1-4 alkoxy, trifluoromethyl, nitro, amino, C 1-4 alkylamino or
- the present invention relates to an antidepressant pharmaceutical composition
- an antidepressant pharmaceutical composition comprising citalopram as the base or any convenient salt thereof manufactured by the process of the invention.
- dehydrating agent' refers to any suitable dehydrating agent, and a person skilled in the art may easily determine the optimal agent.
- suitable dehydrating agents are SOCl 2 , POCl 3 , PC1 5 , SOBr 2 , POBr 3 , PBr 5 , SOI 2 , POI 3 , PI 5 , P O 10; oxalylchloride, carbonyldiimidazole and Vilsmeier reagents.
- a chloro-containing agent most preferably SOCl 2 or POCl 3 , is used.
- C 1-6 alkyl refers to a branched or unbranched alkyl group having from one to six carbon atoms inclusive, such as methyl, ethyl, 1-propyl, 2-pro- pyl, 1 -butyl, 2-butyl, 2-methyl-2-propyl, 2,2-dimethyl-l -ethyl and 2-methyl- 1-propyl.
- C ⁇ -4 alkyl refers to such a group having from one to four carbon atoms inclusive and C 1-6 alkoxy, C 1-4 alkoxy and C 1-4 alkylamine designate such groups wherein the alkyl moity is as defined.
- Halogen means fluorine, chlorine, bromine or iodine.
- one possible but non-limiting mechanism of the reaction is that the 5-carboxy compound of Formula IV reacts with the dehydration agent in order to form a corresponding activated derivative, which then reacts with the sulfonamide, H 2 N-SO - R, thereby forming citalopram.
- a catalytic amount of an acid may be necessary.
- the sulfonamide, H 2 N-SO 2 -R, used in the process is preferably sulfamide, NH -SO 2 -NH 2 .
- the optionally substituted NH 2 used in the process is preferably tert-butylamine.
- the reactions with dehydration agents in the method of the invention are carried out neat or in a suitable solvent, such as sulfolane or acetonitrile.
- a suitable solvent such as sulfolane or acetonitrile.
- a catalytic amount of NN-dimethylformamide may be needed.
- the methods for preparation of citalopram and/or the compounds of Formula IV or Formula VII comprises: a) Reaction of the 5-halo analogue of Formula VIII
- Z is halogen, with Mg or an organolithium compound, e.g. n-BuLi, or with an organometallic complex composed of Mg and/or Mn and/or Li and alkyl or aryl groups and subsequently with CO 2 , CS 2 or a compound of the Formula IX
- a and X are independently selected from halide, CN, OR 5 or SR 6 where R 5 and R 6 are independently selected from C 1-6 alkyl, aryl, heteroaryl or benzyl and each of these C 1-6 alkyl, aryl, heteroaryl or benzyl groups are unsubstituted or substituted with halogen, C 1-4 alkyl, cyano, hydroxy, C 1-4 alkoxy, trifluoromethyl, nitro, amino, C 1- alkylamino or di-C 1-4 alkylamino, NR 7 R 8 where R 7 and R 8 are independently selected from hydrogen, C 1-6 alkyl, aryl, heteroaryl or benzyl and each of these C 1-6 alkyl, aryl, heteroaryl or benzyl groups are unsubstituted or substituted with halogen, C 1-4 alkyl, cyano, hydroxy, C 1-4 alkoxy, trifluoromethyl, nitro, amino, C 1- alkyl,
- organometallic complexes are trialkylmagnesates of the Formula (R 4 ) 3 MgLi, trialkylmangenates of the Formula (R 4 ) 3 MnLi and mixed magnesium and mangenate complexes of the Formula (R 4 ) 3 MnMgBr, wherein R 4 designates C 1-6 -alkyl or aryl groups that may be identical or different.
- Trialkylmagnesate may be prepared in situ from a Grignard reagent R 4 MgX (X is halogen) and an organolithium, e.g. n-butyllithium.
- Trialkylmangenate may be generated in situ from MnCl 2 and an organolithium e.g. n- butyllithium.
- (R 4 ) 3 MnMgBr may be prepared from a Grignard reagent R 4 MgX and MnCl 2 ..
- the starting 5-bromo compound of Formula VIII may be obtained as described in US 4,136,193.
- examples of starting materials of Formula IX are: ethyl chloroformate, phenyl chloroformate, benzyl chloroformate, vinyl chloroformate, isobutyl chloroformate, ethyl chlorothiolformate, methyl cyanoformate, carbonyldiimidazole and diethyl carbonate.
- the starting materials of Formula IX are commercially available or may be prepared by literature methods.
- the nickel based catalyst may be any suitable Ni(0) or Ni(II) containing complex which acts as a catalyst, such as Ni(PPh 3 ) 3 and ( ⁇ -aryl)-Ni(PPh 3 ) 2 Cl
- the palladium based catalyst may be any suitable Pd(0) or Pd(II) containing catalyst, such as Pd(PPh 3 ) 4 , Pd 2 (dba) 3 and Pd(PPh) 2 Cl 2
- the oxidation agent may be any suitable agent, such as a peroxide in the presence of a ruthenium catalyst.
- the starting compounds wherein B is a triflate group may be obtained as described in WO 0013648.
- Examples of the vinyl or acetylenic groups coupled with the compound of Formula VIII are methyl acrylate, 1- bromobut-1-ene, propyne, trimethyl(prop-l-enyl)stannane, E-1-hexenylboronic acid and prop-1-enyl trifluoromethylsulfonate.
- the compound of Formula I may be used as the free base or as a pharmaceutically acceptable acid addition salt thereof.
- acid addition salts such salts formed with organic or inorganic acids may be used.
- organic salts are those with maleic, fumaric, benzoic, ascorbic, succinic, oxalic, bismethylenesahcylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzene sulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8- bromotheophylline.
- inorganic salts are those with hydrochloric, hydrobromic,
- the acid addition salts of the compounds may be prepared by methods known in the art.
- the base is reacted with either the calculated amount of acid in a water miscible solvent, such as acetone or ethanol, with subsequent isolation of the salt by concentration and cooling, or with an excess of the acid in a water immiscible solvent, such as diethylether, ethylacetate or dichloromethane, with the salt separating spontaneously.
- a water miscible solvent such as acetone or ethanol
- a water immiscible solvent such as diethylether, ethylacetate or dichloromethane
- compositions of the invention may be administered in any suitable way and in any suitable form, for example orally in the form of tablets, capsules, powders or syrups, or parenterally in the form of usual sterile solutions for injection.
- the pharmaceutical Formulations of the invention may be prepared by conventional methods in the art.
- tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tabletting maschine.
- adjuvants or diluents comprise: Corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvant or additive colourings, aroma, preservatives etc. may be used provided that they are compatible with the active ingredients.
- Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to the desired volume, sterilising the solution and filling it in suitable ampoules or vials.
- Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Furan Compounds (AREA)
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SI200130273T SI1309581T1 (en) | 2000-08-18 | 2001-08-14 | Method for the preparation of citalopram |
MXPA03001329A MXPA03001329A (en) | 2000-08-18 | 2001-08-14 | METHOD FOR THE PREPARATION OF CITALOPRAM. |
JP2002521442A JP2004506729A (en) | 2000-08-18 | 2001-08-14 | Citalopram manufacturing method |
EP01957785A EP1309581B1 (en) | 2000-08-18 | 2001-08-14 | Method for the preparation of citalopram |
MEP-23/08A MEP2308A (en) | 2000-08-18 | 2001-08-14 | Method for the preparation of citalopram |
PL35982501A PL359825A1 (en) | 2000-08-18 | 2001-08-14 | Method for the preparation of citalopram |
UA2003010798A UA71676C2 (en) | 2000-08-18 | 2001-08-14 | A method for the preparation of citalopram |
DK01957785T DK1309581T3 (en) | 2000-08-18 | 2001-08-14 | Process for the preparation of citalopram |
DK01957786T DK1309582T3 (en) | 2000-08-18 | 2001-08-14 | Process for the preparation of citalopram |
NZ523853A NZ523853A (en) | 2000-08-18 | 2001-08-14 | Method for the preparation of citalopram, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5- isobenzofurancarbonitrile |
EA200300279A EA005946B1 (en) | 2000-08-18 | 2001-08-14 | Method for the preparation of citalopram |
DE60106932T DE60106932T2 (en) | 2000-08-18 | 2001-08-14 | PROCESS FOR THE PREPARATION OF CITALOPRAM |
KR1020037002005A KR100887206B1 (en) | 2000-08-18 | 2001-08-14 | Method for the preparation of citalopram |
AU2001279608A AU2001279608B2 (en) | 2000-08-18 | 2001-08-14 | Method for the preparation of citalopram |
AT01957785T ATE281447T1 (en) | 2000-08-18 | 2001-08-14 | METHOD FOR PRODUCING CITALOPRAM |
SK320-2003A SK287236B6 (en) | 2000-08-18 | 2001-08-14 | Method for the preparation of citalopram, citalopram prepared by this method and pharmaceutical composition comprising same |
AU7960801A AU7960801A (en) | 2000-08-18 | 2001-08-14 | Method for the preparation of citalopram |
HR20030065A HRP20030065A2 (en) | 2000-08-18 | 2003-02-03 | Method for the preparation of citalopram |
BG107583A BG65964B1 (en) | 2000-08-18 | 2003-02-24 | Method for the preparation of citalopram |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200001231 | 2000-08-18 | ||
DKPA200001231 | 2000-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002016341A1 true WO2002016341A1 (en) | 2002-02-28 |
Family
ID=8159660
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2001/000542 WO2002016342A1 (en) | 2000-08-18 | 2001-08-14 | Method for the preparation of citalopram |
PCT/DK2001/000541 WO2002016341A1 (en) | 2000-08-18 | 2001-08-14 | Method for the preparation of citalopram |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2001/000542 WO2002016342A1 (en) | 2000-08-18 | 2001-08-14 | Method for the preparation of citalopram |
Country Status (41)
Country | Link |
---|---|
US (2) | US6509483B2 (en) |
EP (2) | EP1309581B1 (en) |
JP (2) | JP2004506730A (en) |
KR (2) | KR100887206B1 (en) |
CN (3) | CN1159307C (en) |
AR (3) | AR029598A1 (en) |
AT (4) | ATE281447T1 (en) |
AU (6) | AU2001279608B2 (en) |
BE (2) | BE1013443A6 (en) |
BG (2) | BG65965B1 (en) |
CA (2) | CA2354880C (en) |
CH (2) | CH691968A5 (en) |
CL (2) | CL2008002412A1 (en) |
CZ (2) | CZ294746B6 (en) |
DE (4) | DE60106933T2 (en) |
DK (4) | DK1309582T3 (en) |
EA (2) | EA005946B1 (en) |
ES (4) | ES2230347T3 (en) |
FI (2) | FI20011621A (en) |
FR (2) | FR2813078B1 (en) |
GB (2) | GB2362647B (en) |
GR (1) | GR1004074B (en) |
HK (3) | HK1044538B (en) |
HR (2) | HRP20030064A2 (en) |
HU (2) | HUP0103291A3 (en) |
IE (2) | IES20010761A2 (en) |
IL (2) | IL144816A (en) |
IS (2) | IS2121B (en) |
ME (2) | MEP2308A (en) |
MX (2) | MXPA03001329A (en) |
NL (2) | NL1018776C1 (en) |
NO (2) | NO326772B1 (en) |
NZ (2) | NZ523877A (en) |
PL (2) | PL359825A1 (en) |
PT (2) | PT1309582E (en) |
RS (2) | RS50258B (en) |
SI (2) | SI1309582T1 (en) |
SK (2) | SK287236B6 (en) |
UA (2) | UA72340C2 (en) |
WO (2) | WO2002016342A1 (en) |
ZA (1) | ZA200106683B (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR022329A1 (en) | 1999-01-29 | 2002-09-04 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF 5-CYANOFTALIDE |
ATE237604T1 (en) * | 1999-04-14 | 2003-05-15 | Lundbeck & Co As H | METHOD FOR PRODUCING CITALOPRAM |
ITMI991581A1 (en) * | 1999-06-25 | 2001-01-15 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF CITALOPRAM |
DE19983836C1 (en) | 1999-10-25 | 2003-10-23 | Lundbeck As Valby H | Process for the preparation of citalopram, 4- [1- (4-fluorophenyl) methanoyl] benzonitrile derivatives and process for their preparation and their use |
AR026063A1 (en) | 1999-11-01 | 2002-12-26 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF 5-CARBOXIFTALIDA. |
EA004742B1 (en) | 1999-12-28 | 2004-08-26 | Х.Лундбекк А/С | Method for the preparation of citalopram |
JP2003519218A (en) | 1999-12-30 | 2003-06-17 | ハー・ルンドベック・アクチエゼルスカベット | Method for producing citalopram |
SI1254129T1 (en) * | 2000-01-14 | 2004-02-29 | H. Lundbeck A/S | Method for the preparation of 5-cyanophthalide |
NL1017417C1 (en) | 2000-03-03 | 2001-03-16 | Lundbeck & Co As H | Process for the preparation of Citalopram. |
CN1429219A (en) | 2000-03-13 | 2003-07-09 | H·隆德贝克有限公司 | Method for preparation of citalopram |
NL1017500C1 (en) | 2000-03-13 | 2001-04-26 | Lundbeck & Co As H | Process for the preparation of Citalopram. |
NZ521204A (en) * | 2000-03-13 | 2004-03-26 | H | Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)- 1,3-dihydroisobenzofurans for preparing citalopram, an anti depressant |
WO2001068630A1 (en) | 2000-03-14 | 2001-09-20 | H. Lundbeck A/S | Method for the preparation of citalopram |
TR200202168T2 (en) * | 2000-03-16 | 2002-12-23 | H. Lundbeck A/S | Preparation method of 5-Cyano-1- (4-Fluorophenyl) -1,3-Dihydroisobenzofurans |
AR032455A1 (en) | 2000-05-12 | 2003-11-12 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF CITALOPRAM, AN INTERMEDIARY EMPLOYED IN THE METHOD, A METHOD FOR THE PREPARATION OF THE INTERMEDIARY EMPLOYED IN THE METHOD AND PHARMACEUTICAL COMPOSITION ANTIDEPRESSIVE |
IL144816A (en) | 2000-08-18 | 2005-09-25 | Lundbeck & Co As H | Method for the preparation of citalopram |
SG167655A1 (en) | 2000-12-22 | 2011-01-28 | Lundbeck & Co As H | Method for the preparation of pure citalopram |
WO2003057132A2 (en) * | 2002-01-07 | 2003-07-17 | Sun Pharmaceutical Industries Limited | Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile |
AR040970A1 (en) * | 2002-08-12 | 2005-04-27 | Lundbeck & Co As H | METHOD FOR THE SEPARATION OF INTERMEDIARIES THAT CAN BE USED FOR THE PREPARATION OF SCITALOPRAM |
TR200504022T1 (en) * | 2003-03-24 | 2006-08-21 | Hetero Drugs Limited | New liquid crystal forms of (S) -sitalopram oxalate. |
US20050143350A1 (en) * | 2003-11-19 | 2005-06-30 | Seed John C. | Combination drug therapy to treat obesity |
CN100569765C (en) | 2003-12-19 | 2009-12-16 | 杭州民生药业集团有限公司 | Citalopram intermediate crystalline base |
US9339500B2 (en) * | 2008-03-04 | 2016-05-17 | Intra-Cellular Therapies, Inc. | Methods of treating vasomotor symptoms |
US20100087664A1 (en) * | 2008-10-07 | 2010-04-08 | Ravindra Vedantham | Preparation of citalopram and salts thereof |
JP6222973B2 (en) * | 2013-04-19 | 2017-11-01 | 日本テルペン化学株式会社 | Dibenzyltrithiocarbonate derivative |
CN103936702A (en) * | 2014-05-07 | 2014-07-23 | 成都诺维尔生物医药有限公司 | Synthetic method of escitalopram impurity J |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4136193A (en) * | 1976-01-14 | 1979-01-23 | Kefalas A/S | Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans |
WO1998019513A2 (en) * | 1997-07-08 | 1998-05-14 | H. Lundbeck A/S | Method for the preparation of citalopram |
WO2000011926A2 (en) * | 1999-06-25 | 2000-03-09 | H. Lundbeck A/S | Method for the preparation of citalopram |
WO2000013648A2 (en) * | 1999-06-25 | 2000-03-16 | H. Lundbeck A/S | Method for the preparation of citalopram |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1143702A (en) | 1965-03-18 | |||
GB8419963D0 (en) | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
GB8814057D0 (en) | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
DE3926765A1 (en) | 1989-08-12 | 1991-02-14 | Hoechst Ag | METHOD FOR REDUCING PRIMARY AND SECOND AMINE IN A TERTIA AMINE |
US5296507A (en) | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
DK213290D0 (en) | 1990-09-06 | 1990-09-06 | Lundbeck & Co As H | TREATMENT OF CEREBROVASCULAR DISORDERS |
DE19626659A1 (en) | 1996-07-03 | 1998-01-08 | Basf Ag | Process for the production of phthalides |
DE19627697A1 (en) | 1996-07-10 | 1998-01-15 | Basf Ag | Process for the production of phthalides |
ZA9711376B (en) | 1996-12-20 | 1998-07-21 | Lundbeck & Co As H | Indole or dihydroindole derivatives |
UA62985C2 (en) | 1997-11-10 | 2004-01-15 | Lunnbeck As H | A method for the preparation of citalopram |
ES2149734T3 (en) | 1997-11-11 | 2003-02-16 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF CITALOPRAM. |
CN1129592C (en) | 1998-10-20 | 2003-12-03 | H·隆德贝克有限公司 | Method for the preparation of citalopram |
SI1140886T1 (en) | 1998-12-23 | 2003-08-31 | H. Lundbeck A/S | Method for the preparation of 5-cyanophthalide |
AR022329A1 (en) | 1999-01-29 | 2002-09-04 | Lundbeck & Co As H | METHOD FOR THE PREPARATION OF 5-CYANOFTALIDE |
ATE237604T1 (en) | 1999-04-14 | 2003-05-15 | Lundbeck & Co As H | METHOD FOR PRODUCING CITALOPRAM |
EP1228056B1 (en) | 1999-10-25 | 2004-09-22 | H. Lundbeck A/S | Method for the preparation of citalopram |
US6310222B1 (en) | 1999-11-01 | 2001-10-30 | Sumika Fine Chemicals Co., Ltd. | Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate |
NL1017415C1 (en) | 2000-02-24 | 2001-05-18 | Lundbeck & Co As H | Process for the preparation of Citalopram. |
IES20010143A2 (en) | 2000-02-24 | 2001-07-25 | Lundbeck & Co As H | Method for the preparation of citalopram |
GB0005477D0 (en) * | 2000-03-07 | 2000-04-26 | Resolution Chemicals Limited | Process for the preparation of citalopram |
IL144816A (en) | 2000-08-18 | 2005-09-25 | Lundbeck & Co As H | Method for the preparation of citalopram |
SG167655A1 (en) | 2000-12-22 | 2011-01-28 | Lundbeck & Co As H | Method for the preparation of pure citalopram |
JP2003519121A (en) | 2000-12-28 | 2003-06-17 | ハー・ルンドベック・アクチエゼルスカベット | Method for producing pure citalopram |
-
2001
- 2001-08-09 IL IL14481601A patent/IL144816A/en not_active IP Right Cessation
- 2001-08-09 FI FI20011621A patent/FI20011621A/en unknown
- 2001-08-09 CA CA002354880A patent/CA2354880C/en not_active Expired - Fee Related
- 2001-08-09 CA CA002354877A patent/CA2354877C/en not_active Expired - Fee Related
- 2001-08-09 FI FI20011622A patent/FI20011622A/en unknown
- 2001-08-09 IL IL14481701A patent/IL144817A0/en not_active IP Right Cessation
- 2001-08-10 IS IS6048A patent/IS2121B/en unknown
- 2001-08-10 IS IS6047A patent/IS2120B/en unknown
- 2001-08-10 HU HU0103291A patent/HUP0103291A3/en unknown
- 2001-08-13 IE IE20010761A patent/IES20010761A2/en not_active IP Right Cessation
- 2001-08-13 IE IE20010760A patent/IES20010760A2/en not_active IP Right Cessation
- 2001-08-13 HU HU0103295A patent/HUP0103295A3/en unknown
- 2001-08-14 JP JP2002521443A patent/JP2004506730A/en not_active Withdrawn
- 2001-08-14 NO NO20013942A patent/NO326772B1/en not_active IP Right Cessation
- 2001-08-14 ME MEP-23/08A patent/MEP2308A/en unknown
- 2001-08-14 NO NO20013943A patent/NO326570B1/en not_active IP Right Cessation
- 2001-08-14 EP EP01957785A patent/EP1309581B1/en not_active Expired - Lifetime
- 2001-08-14 SI SI200130272T patent/SI1309582T1/en unknown
- 2001-08-14 ME MEP-22/08A patent/MEP2208A/en unknown
- 2001-08-14 DK DK01957786T patent/DK1309582T3/en active
- 2001-08-14 AU AU2001279608A patent/AU2001279608B2/en not_active Ceased
- 2001-08-14 DK DK200101219A patent/DK200101219A/en not_active Application Discontinuation
- 2001-08-14 AT AT01957785T patent/ATE281447T1/en not_active IP Right Cessation
- 2001-08-14 DK DK200101216A patent/DK200101216A/en not_active Application Discontinuation
- 2001-08-14 PL PL35982501A patent/PL359825A1/en not_active Application Discontinuation
- 2001-08-14 ES ES01957785T patent/ES2230347T3/en not_active Expired - Lifetime
- 2001-08-14 RS YU6903A patent/RS50258B/en unknown
- 2001-08-14 UA UA2003010797A patent/UA72340C2/en unknown
- 2001-08-14 PT PT01957786T patent/PT1309582E/en unknown
- 2001-08-14 EA EA200300279A patent/EA005946B1/en not_active IP Right Cessation
- 2001-08-14 DK DK01957785T patent/DK1309581T3/en active
- 2001-08-14 WO PCT/DK2001/000542 patent/WO2002016342A1/en active IP Right Grant
- 2001-08-14 KR KR1020037002005A patent/KR100887206B1/en not_active IP Right Cessation
- 2001-08-14 AT AT01957786T patent/ATE281448T1/en not_active IP Right Cessation
- 2001-08-14 UA UA2003010798A patent/UA71676C2/en unknown
- 2001-08-14 MX MXPA03001329A patent/MXPA03001329A/en active IP Right Grant
- 2001-08-14 ES ES01957786T patent/ES2228920T3/en not_active Expired - Lifetime
- 2001-08-14 DE DE60106933T patent/DE60106933T2/en not_active Expired - Lifetime
- 2001-08-14 SI SI200130273T patent/SI1309581T1/en unknown
- 2001-08-14 GR GR20010100398A patent/GR1004074B/en unknown
- 2001-08-14 KR KR1020037001900A patent/KR100887207B1/en not_active IP Right Cessation
- 2001-08-14 NZ NZ523877A patent/NZ523877A/en unknown
- 2001-08-14 DE DE60106932T patent/DE60106932T2/en not_active Expired - Lifetime
- 2001-08-14 GB GB0119733A patent/GB2362647B/en not_active Expired - Fee Related
- 2001-08-14 JP JP2002521442A patent/JP2004506729A/en not_active Withdrawn
- 2001-08-14 GB GB0119734A patent/GB2365865B/en not_active Expired - Fee Related
- 2001-08-14 AU AU7960901A patent/AU7960901A/en active Pending
- 2001-08-14 PL PL35996901A patent/PL359969A1/en not_active Application Discontinuation
- 2001-08-14 PT PT01957785T patent/PT1309581E/en unknown
- 2001-08-14 AU AU2001279609A patent/AU2001279609B2/en not_active Ceased
- 2001-08-14 ZA ZA200106683A patent/ZA200106683B/en unknown
- 2001-08-14 RS YUP-115/03A patent/RS50287B/en unknown
- 2001-08-14 EP EP01957786A patent/EP1309582B1/en not_active Expired - Lifetime
- 2001-08-14 AU AU7960801A patent/AU7960801A/en active Pending
- 2001-08-14 US US09/930,110 patent/US6509483B2/en not_active Expired - Fee Related
- 2001-08-14 WO PCT/DK2001/000541 patent/WO2002016341A1/en active IP Right Grant
- 2001-08-14 US US09/930,107 patent/US6426422B1/en not_active Expired - Fee Related
- 2001-08-14 MX MXPA03000913A patent/MXPA03000913A/en active IP Right Grant
- 2001-08-14 SK SK320-2003A patent/SK287236B6/en not_active IP Right Cessation
- 2001-08-14 NZ NZ523853A patent/NZ523853A/en unknown
- 2001-08-14 EA EA200300277A patent/EA005811B1/en not_active IP Right Cessation
- 2001-08-14 SK SK322-2003A patent/SK287008B6/en not_active IP Right Cessation
- 2001-08-15 CZ CZ20012958A patent/CZ294746B6/en not_active IP Right Cessation
- 2001-08-15 AU AU2001100271A patent/AU2001100271B4/en not_active Expired
- 2001-08-15 CZ CZ20012959A patent/CZ295863B6/en not_active IP Right Cessation
- 2001-08-16 AU AU2001100278A patent/AU2001100278B4/en not_active Expired
- 2001-08-16 BE BE2001/0548A patent/BE1013443A6/en not_active IP Right Cessation
- 2001-08-16 DE DE10140028A patent/DE10140028A1/en not_active Withdrawn
- 2001-08-16 AR ARP010103924A patent/AR029598A1/en not_active Application Discontinuation
- 2001-08-16 DE DE10140029A patent/DE10140029A1/en not_active Withdrawn
- 2001-08-16 CH CH01521/01A patent/CH691968A5/en not_active IP Right Cessation
- 2001-08-16 FR FR0110857A patent/FR2813078B1/en not_active Expired - Fee Related
- 2001-08-16 NL NL1018776A patent/NL1018776C1/en not_active IP Right Cessation
- 2001-08-16 NL NL1018775A patent/NL1018775C1/en not_active IP Right Cessation
- 2001-08-16 AR ARP010103923A patent/AR029597A1/en not_active Application Discontinuation
- 2001-08-16 FR FR0110855A patent/FR2813077B1/en not_active Expired - Fee Related
- 2001-08-16 CH CH01522/01A patent/CH691969A5/en not_active IP Right Cessation
- 2001-08-17 CN CNB011339470A patent/CN1159307C/en not_active Expired - Fee Related
- 2001-08-17 ES ES200101920A patent/ES2170735B2/en not_active Expired - Fee Related
- 2001-08-17 CN CNB2004100018711A patent/CN1239490C/en not_active Expired - Fee Related
- 2001-08-17 ES ES200101919A patent/ES2170734B2/en not_active Expired - Fee Related
- 2001-08-17 CN CNB011339489A patent/CN1222517C/en not_active Expired - Fee Related
- 2001-08-17 AT AT0065001U patent/AT4946U1/en not_active IP Right Cessation
- 2001-08-17 AT AT0065101U patent/AT5026U1/en not_active IP Right Cessation
- 2001-08-20 BE BE2001/0550A patent/BE1013444A6/en not_active IP Right Cessation
-
2002
- 2002-08-22 HK HK02106176.1A patent/HK1044538B/en not_active IP Right Cessation
- 2002-09-04 HK HK05100254A patent/HK1068069A1/en not_active IP Right Cessation
- 2002-09-04 HK HK02106522.2A patent/HK1047086B/en not_active IP Right Cessation
-
2003
- 2003-02-03 HR HR20030064A patent/HRP20030064A2/en not_active Application Discontinuation
- 2003-02-03 HR HR20030065A patent/HRP20030065A2/en not_active Application Discontinuation
- 2003-02-24 BG BG107584A patent/BG65965B1/en unknown
- 2003-02-24 BG BG107583A patent/BG65964B1/en unknown
-
2008
- 2008-04-25 AR ARP080101772A patent/AR066694A2/en unknown
- 2008-08-14 CL CL2008002412A patent/CL2008002412A1/en unknown
- 2008-09-09 CL CL2008002673A patent/CL2008002673A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4136193A (en) * | 1976-01-14 | 1979-01-23 | Kefalas A/S | Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans |
WO1998019513A2 (en) * | 1997-07-08 | 1998-05-14 | H. Lundbeck A/S | Method for the preparation of citalopram |
WO2000011926A2 (en) * | 1999-06-25 | 2000-03-09 | H. Lundbeck A/S | Method for the preparation of citalopram |
WO2000013648A2 (en) * | 1999-06-25 | 2000-03-16 | H. Lundbeck A/S | Method for the preparation of citalopram |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1309581B1 (en) | Method for the preparation of citalopram | |
AU2001279608A1 (en) | Method for the preparation of citalopram | |
EP1159274B1 (en) | Method for the preparation of citalopram | |
US6291689B1 (en) | Method for the preparation of citalopram | |
JP3389571B2 (en) | Method for producing citalopram | |
AU2001279609A1 (en) | Method for the preparation of citalopram |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1200300261 Country of ref document: VN Ref document number: P-115/03 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 523853 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20030065A Country of ref document: HR Ref document number: 2001957785 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037002005 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/001329 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002521442 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 10758301 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001279608 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3202003 Country of ref document: SK |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037002005 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200300279 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 2001957785 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 523853 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001957785 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 523853 Country of ref document: NZ |